Meeting
2022 ASCO Annual Meeting
Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Updated final results of the randomized phase II AIO-NEONAX trial.
Authors
Thomas Jens Ettrich
Ulm University Hospital, Department of Internal Medicine I, Ulm, Germany
Thomas Jens Ettrich , Waldemar Uhl , Marko Kornmann , Hana Algül , Helmut Friess , Alexander Koenig , Eike Gallmeier , Manfred P. Lutz , Kai Wille , Carl Christoph Schimanski , Volker Kunzmann , Michael Geissler , Dirk Waldschmidt , Severin Daum , Lisa Blome , Andrea Tannapfel , Lukas Perkhofer , Margaret A. Tempero , Anke C. Reinacher-Schick , Thomas Seufferlein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT02047513
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4133)
DOI
10.1200/JCO.2022.40.16_suppl.4133
Abstract #
4133
Poster Bd #
119
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313)— Safety interim analysis.
First Author: Waldemar Uhl
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial.
First Author: Sina Buchholz
Poster
2024 ASCO Gastrointestinal Cancers Symposium
PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.
First Author: Derek B. Grose
Poster
2019 ASCO Annual Meeting
PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.
First Author: Derek B. Grose